Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 2 de 2
Filter
Add more filters










Database
Language
Publication year range
1.
Innate Immun ; 14(4): 247-53, 2008 Aug.
Article in English | MEDLINE | ID: mdl-18669610

ABSTRACT

INTRODUCTION: Periodontitis patients are known to suffer from endotoxemia, which may be among the major risk factors for atherosclerosis. In health, lipopolysaccharide (LPS) is mainly carried with high density lipoprotein (HDL) particles. Shift of LPS toward lipoproteins with lower densities may result in less effective endotoxin scavenging. Our aim was to determine plasma LPS activity and lipoprotein-distribution before and after treatment in periodontitis patients. PATIENTS AND METHODS: Very low and intermediate density (VLDL-IDL), low density (LDL), HDL 2, HDL3, and lipoprotein-deficient plasma (LPDP) were isolated by sequential ultracentrifugation. Patients included 34 subjects aged 53.5 +/- 8.3 years, before and 6 months after periodontal treatment. RESULTS: The mean LPS distribution decreased among lipoprotein classes as follows: VLDL-IDL 41.3 +/- 12.1%, LPDP 25.0 +/- 7.0%, HDL3 13.1 +/- 5.2%, LDL 11.5 +/- 3.7%, and HDL2 9.2 +/- 2.8%. Plasma and VLDL-IDL-associated LPS correlated positively, and LDL- and HDL-associated LPS negatively with clinical periodontal parameters and plasma cytokine concentrations. Mean plasma LPS activity increased after periodontal treatment from 44.0 +/- 17.0 to 55.7 +/- 24.2 EU/ml (P = 0.006). No significant changes were found in LPS lipoprotein distribution and lipoprotein compositions after the treatment. CONCLUSIONS: Endotoxemia increases with severity of periodontitis. In periodontitis, LPS associates preferentially with the pro-atherogenic VLDL-IDL fraction. Periodontal treatment has only minor effects on plasma LPS activity or distribution, which reflects persistence of the disease.


Subject(s)
Lipopolysaccharides/blood , Lipoproteins/blood , Periodontitis/blood , Atherosclerosis/blood , Atherosclerosis/etiology , Atherosclerosis/immunology , Biological Transport, Active , Endocytosis/immunology , Endotoxemia/blood , Endotoxemia/immunology , Female , Humans , Lipopolysaccharides/immunology , Lipoproteins/chemistry , Lipoproteins/immunology , Macrophages/immunology , Male , Middle Aged , Periodontitis/drug therapy , Periodontitis/immunology , Protein Binding , Severity of Illness Index
2.
Int J Biochem Cell Biol ; 35(2): 192-202, 2003 Feb.
Article in English | MEDLINE | ID: mdl-12479869

ABSTRACT

The two main functions of phospholipid transfer protein (PLTP) are the transfer of phospholipids between plasma lipoproteins and the conversion of high density lipoprotein (HDL), where prebeta-HDL particles are generated. HDL is considered an anti-atherogenic lipoprotein due to its function in the reverse cholesterol transport, where prebeta-HDL accepts cellular membrane cholesterol from peripheral tissues. However, the anti-atherogenic properties of native HDL may be abolished by oxidation/modification. Hypochlorous acid/hypochlorite (HOCl/OCl-)-a potent oxidant generated in vivo only by the myeloperoxidase-H2O2-chloride system of activated phagocytes-alters the physiological properties of HDL by generating a pro-atherogenic lipoprotein particle. Therefore, we have studied the effect of HOCl on the function of HDL subclass 3 (HDL3) and triglyceride-enriched HDL3 (TG-HDL3) in PLTP-mediated processes in vitro. Modification of HDL3 and TG-HDL3 with increasing HOCl concentrations (oxidant:lipoprotein molar ratio between 25:1 and 200:1) decreased the capacity of the corresponding lipoprotein particles to accept phospholipids. Although binding of PLTP to unmodified and HOCl-modified lipoprotein particles was similar, the degree of PLTP-mediated HDL conversion was decreased upon HOCl oxidation. PLTP released apolipoprotein A-I (apoA-I) from HOCl-modified HDL3, but the particles formed displayed no prebeta-mobility. Based on these findings, we conclude that the substrate properties of HOCl-modified HDL3 and TG-HDL3 in PLTP-mediated processes are impaired, which indicates that the anti-atherogenic properties of HDL are impaired.


Subject(s)
Carrier Proteins/metabolism , Hypochlorous Acid/pharmacology , Lipoproteins, HDL/metabolism , Membrane Proteins/metabolism , Phospholipid Transfer Proteins , Apolipoprotein A-I/chemistry , Apolipoprotein A-I/metabolism , Carrier Proteins/blood , Carrier Proteins/drug effects , Dose-Response Relationship, Drug , Humans , Hypochlorous Acid/chemistry , Lipoproteins, HDL/chemistry , Lipoproteins, HDL/drug effects , Lipoproteins, HDL3 , Membrane Proteins/blood , Membrane Proteins/drug effects , Oxidation-Reduction/drug effects , Protein Binding/drug effects , Triglycerides/chemistry , Triglycerides/metabolism
SELECTION OF CITATIONS
SEARCH DETAIL
...